Peptide Library
MetabolicTH9507Egrifta

Tesamorelin

A stabilized GHRH analog studied for visceral adipose tissue reduction.

Add to a stack

Half-life

~25–40 minutes

Schedule

daily

Cycle

12–26 wks

Mechanism of action

Potent GHRH receptor agonist increasing GH/IGF-1, with notable effects on visceral fat in clinical research.

Potential applications

Visceral fat researchMetabolic

Dosing information

Clinical research has used ~1–2 mg daily subcutaneously.

For research and educational reference only — not a dosing recommendation.

Research references

Aether Pulse provides educational and research information only. Content is not medical advice. Products are sold for research use only. Consult a qualified professional before making health decisions.